Introduction {#s1}
============

Skeletal muscle plays an important role in regulating resting metabolism, lipid oxidation, postprandial glucose disposal, and locomotion \[[@R01]\]. Muscle mass and function loss can also lead to reduction in physical activity, which may negatively affect metabolic processes (e.g. osteoporosis, obesity, and impaired glucose tolerance) \[[@R02]\]. In addition to improving sports performance, promoting muscular hypertrophy can improve muscle mass and function, which can subsequently increase quality of life and reduce the risks of various diseases.

Repeated bouts of anabolic stimulation (e.g. resistance training) increase muscle mass and improve muscle function by inducing muscle hypertrophy \[[@R03]\]. However, besides resistance exercise, nutrient intake can also stimulate muscle protein synthesis \[[@R04]\]. Protein and amino acid consumption promotes muscle protein synthesis by increasing amino acid blood levels and enhancing amino acid transport to muscle cells \[[@R05], [@R06]\]. Thus, amino acid and protein supplementation with resistance exercise augments muscle protein synthesis, compared to resistance exercise alone \[[@R07]\].

Different protein sources have distinct qualitative effects on muscle anabolism. Whey protein is rapidly digested and its high essential amino acid levels include branched-chain amino acids. In humans, ingestion of whey protein at rest and after resistance exercise stimulates muscle protein synthesis \[[@R08], [@R9]\] and promotes increases in lean body mass, compared to ingestion of other protein sources (e.g. casein and soy protein) \[[@R10], [@R11]\], although not all studies agree with the superiority of whey over casein \[[@R12], [@R13]\]. Therefore, milk-based proteins (e.g. whey) combined with resistance exercise are effective for promoting muscular hypertrophy.

Gamma-aminobutyric acid (GABA) is a widely distributed amino acid found in foods, such as vegetables, fruits, and fermented foods. In vertebrates, GABA exists in the brain and acts as an inhibitory neurotransmitter in the central nervous system \[[@R14]\]. Oral GABA administration relieves anxiety \[[@R15]\], reduces psychological stress \[[@R16]\], induces relaxation \[[@R17]\], and improves sleep \[[@R18]\] by increasing total and parasympathetic nerve activities \[[@R19]\]. GABA also supports the physiologic adjustment of pituitary gland function and controls growth hormone (GH) secretion from the pituitary gland \[[@R20], [@R21]\]. Thus, GH plays an important role in skeletal muscle growth and maintenance \[[@R22]\]. GH has acute stimulatory effects on amino acid transport \[[@R23]\] and insulin growth factor-1 production, which promotes muscle protein synthesis \[[@R24]\]. GABA administration in humans elevated plasma GH concentrations at rest \[[@R25], [@R26]\]. Moreover, GABA administration in male rats for 10 days increased resting plasma GH concentrations and promoted protein synthesis at baseline in the gastrocnemius muscle, brain, and liver \[[@R27]\]. Conversely, in hypophysectomized rats, GABA does not stimulate GH secretion; hence, GABA-induced GH-concentration increase may influence the pituitary gland \[[@R28]\]. Augmented basal GH concentration by intravenous human recombinant GH (hrGH) administration in young men significantly increased muscle protein synthesis at rest \[[@R29]\]. Additionally, daily hrGH administration in old women for 4 weeks showed a 50% increase in muscle protein synthesis at rest \[[@R30]\]. Although these indicate that basal GH level may modulate muscle protein turnover, no study has investigated effects of increased basal GH plus resistance training on muscle hypertrophy.

We aimed to examine the effects of oral GABA plus whey protein supplementation on muscular hypertrophy in men after progressive resistance training. We hypothesized that GABA administration with post-exercise protein supplementation may enhance training-induced muscle hypertrophy concomitant with elevated resting plasma GH concentrations.

Materials and Methods {#s2}
=====================

Subjects {#s2a}
--------

We included 26 healthy and physically active Japanese men (26 - 48 years) who did not exercise regularly. They were screened based on absence of clinical history, normal blood pressure values, and absence of specific lifestyle factors (e.g. sleep time and physical activity). All subjects provided written informed consent before participation; this study was approved by the Ethics Committee of Pharma Foods International Co., Ltd. All procedures were performed in accordance with the tenets of the Declaration of Helsinki.

Study design {#s2b}
------------

We used a randomized double-blind parallel-group design. The 26 subjects were randomized into two groups that received daily whey protein doses (WP, n = 13) or whey protein and GABA (WP + GABA, n = 13) for 12 weeks and performed resistance exercise twice per week. Body composition and maximal strength were measured at baseline and after 12 weeks. Resting plasma GH concentrations were assessed at baseline, 4, 8, and 12 weeks. Blood sampling was performed after an overnight fast on a non-exercise day morning. Dietary habits were assessed using a brief-type self-administered diet history questionnaire (BDHQ) \[[@R31]\] at baseline and 12 weeks.

Supplements {#s2c}
-----------

The WP group ingested 10 g whey protein powder (36.1 kcal, 8.85 g protein); the WP + GABA group ingested a mixed powder (36.6 kcal) that contained 10 g whey protein powder and 125 mg GABA powder (0.5 kcal, 100 mg GABA). Subjects were instructed to ingest the supplements within 15 min of training, or before sleep on a non-exercise day. Each supplement was dissolved in 150 mL water immediately before ingestion. The whey protein powder was a whey protein isolate (Lactocrystal^®^; Nippon Shinyaku Co., Ltd, Kyoto, Japan); the GABA powder was produced through natural fermentation using a specific lactic acid bacteria strain (Pharma GABA^®^; 80% purity; Pharma Foods International Co., Ltd, Kyoto, Japan).

Resistance training program {#s2d}
---------------------------

The resistance training program included five upper-body and lower-body exercises: leg press, leg extension, leg curl, chest press, and pull down (LifeFitness, Schiller Park, IL, USA). Both groups performed the same training program. Training sessions were completed within 60 min and included the following: 5 min, warm-up (ergometer cycling); 45 min, resistance exercise; and 10 min, stretching exercise. This training program was performed twice per week in a fitness club with training equipment and included one unsupervised and one professional trainer-supervised session per week. All resistance exercises were performed in three sets (12 repetitions; 2 - 3 min rest periods). Maximal strength was measured at baseline and after 12 weeks using the indirect measurement technique. The warm-up load was estimated to allow the subject to complete 5 - 8 repetitions. Weight was increased gradually until a failed attempt or until appropriate form was not maintained. The percentage of repetition maximum (RM) was determined based on number of repetitions. Maximal strength was calculated by dividing weight by percentage of RM \[[@R32]\]. Exercise intensity was set at 50% maximal strength for the first week and then raised to 60% after week 1. Weights were progressively increased in 2.5 - 5 kg intervals when the prescribed repetitions could be completed. The trainer ensured that subjects provided maximum effort and intensity for all supervised training sessions. Subjects were instructed to only perform exercises as part of the training program; those who missed three exercise sessions were excluded from the analysis.

Body composition and plasma measurements {#s2e}
----------------------------------------

Body composition (fat-free mass, fat mass, and total body mass) was assessed for all subjects using dual energy X-ray absorptiometry (GE Healthcare, Madison, WI, USA). Blood samples were centrifuged at 3,000 rpm for 15 min to isolate plasma fractions. Plasma GH concentrations were measured using a commercially available enzyme-linked immunosorbent assay for human GH (R&D Systems, Minneapolis, MN, USA).

Statistical analysis {#s2f}
--------------------

Mean and standard deviation (SD) were used for descriptive statistics. A 2 × 2 repeated-measure analysis of variance was used to assess inter-group differences (WP vs. WP + GABA) and differences between the time points. *Post hoc* comparisons were analyzed using the Bonferroni test. The two-tailed unpaired Student's *t*-test was used to compare changes in fat-free mass between the groups (WP vs. WP + GABA). Differences were considered significant at P values \< 0.05. Statistical analyses were performed using Microsoft Excel version 2013-version 15.0.4849.1003 (Microsoft, Redmond, WA, USA). The University Hospital Medical Information Network (UMIN) Clinical Trials Registry number is UMIN000025842.

Results {#s3}
=======

Participant characteristics and compliance {#s3a}
------------------------------------------

The 26 men were randomized into the WP or WP + GABA groups; age and body composition did not differ between groups. Five subjects were subsequently excluded from the analysis because of personal reasons (WP, n = 1; WP + GABA, n = 1), not completing 90% of supplement intake requirements (WP, n = 1), and not completing 90% of exercise sessions (WP, n = 1; WP + GABA, n = 1). Thus, 21 subjects completed the 12-week program (WP, n = 10, 40.1 ± 7.9 years; WP + GABA, n = 11, 38.8 ± 5.7 years).

Dietary intake {#s3a1}
--------------

There were no significant intra-group (at baseline vs. 12 weeks) or inter-group (WP group vs. WP + GABA group) differences in the dietary intake values ([Table 1](#T1){ref-type="table"}).

###### Nutritional Intake Values at Baseline and After 12 Weeks

                                WP group        WP + GABA group   ANOVA                       
  ----------------------------- --------------- ----------------- ------------- ------------- ----------------------------------------------
  Energy intake (kcal/day)      2,153 ± 1,034   2,105 ± 723       1,681 ± 585   1,761 ± 395   G: P = 0.186, T: P = 0.907, G × T: P = 0.651
  Protein intake (g/day)        69 ± 24         75 ± 24           61 ± 26       62 ± 20       G: P = 0.302, T: P = 0.431, G × T: P = 0.488
  Carbohydrate intake (g/day)   303 ± 170       299 ± 125         219 ± 79      218 ± 58      G: P = 0.103, T: P = 0.913, G × T: P = 0.925
  Fat intake (g/day)            53 ± 19         54 ± 18           49 ± 21       50 ± 15       G: P = 0.608, T: P = 0.809, G × T: P = 0.957

Data are reported as mean ± standard deviation. WP: whey protein; WP + GABA: whey protein + gamma-aminobutyric acid; ANOVA: analysis of variance; G: group effect; T: time effect; G × T: group × time effect.

Maximal strength {#s3a2}
----------------

The mean maximal strength for each exercise was improved after 12 weeks ([Table 2](#T2){ref-type="table"}). Lower body maximal strength significantly improved within each group after resistance training (leg press, leg extension, and leg curl: all P \< 0.05), although there were no significant inter-group differences. Upper body maximal strength also significantly improved within each group after resistance training (chest press and pull down: both P \< 0.05), although there were no significant inter-group differences.

###### Maximal Strength Values at Baseline and After 12 Weeks

                       WP group   WP + GABA group   ANOVA                 
  -------------------- ---------- ----------------- ---------- ---------- ----------------------------------------------
  Leg press (kg)       127 ± 31   202 ± 53          133 ± 38   230 ± 74   G: P = 0.414, T: P = 0.000, G × T: P = 0.404
  Leg extension (kg)   64 ± 17    91 ± 33           64 ± 13    91 ± 15    G: P = 0.968, T: P = 0.000, G × T: P = 0.947
  Leg curl (kg)        53 ± 14    77 ± 22           55 ± 11    78 ± 19    G: P = 0.866, T: P = 0.000, G × T: P = 0.929
  Chest press (kg)     52 ± 11    65 ± 13           63 ± 14    78 ± 16    G: P = 0.058, T: P = 0.000, G × T: P = 0.727
  Pull down (kg)       59 ± 15    73 ± 15           65 ± 15    78 ± 15    G: P = 0.411, T: P = 0.000, G × T: P = 0.876

Data are reported as mean ± standard deviation. WP: whey protein; WP + GABA: whey protein + gamma-aminobutyric acid; ANOVA: analysis of variance; G: group effect; T: time effect; G × T: group × time effect.

Resting plasma GH concentrations {#s3a3}
--------------------------------

The WP + GABA group exhibited significantly higher resting plasma GH concentrations at weeks 4 and 8, compared to baseline (P \< 0.05, [Fig. 1](#F1){ref-type="fig"}). The WP group exhibited significantly higher concentrations only at week 8, compared to baseline (P \< 0.05). However, there were no significant inter-group differences.

![Resting plasma growth hormone concentrations. Values represent the mean ± standard error for 10 subjects (the whey protein group (WP)) or 11 subjects (the whey protein + gamma-aminobutyric acid group (WP + GABA)). \*P \< 0.05 vs. baseline of the WP + GABA group; \*\*P \< 0.05 vs. baseline of the WP group.](jocmr-11-428-g001){#F1}

Body weight and composition {#s3a4}
---------------------------

There was a significant time effect (P \< 0.05) and group × time interaction effect (P \<0.05) for whole body fat-free mass ([Table 3](#T3){ref-type="table"}). However, no significant differences within or between group were detected with *post hoc* test. There was also a significant time effect (P \< 0.05) for arm and leg lean mass, although there was no significant group effect by time-interaction. Body weight, body mass index (BMI), and fat mass did not change significantly after 12 weeks.

###### Body Composition at Baseline and After 12 Weeks

                                  WP group     WP + GABA group   ANOVA                      
  ------------------------------- ------------ ----------------- ------------ ------------- ----------------------------------------------
  Weight (kg)                     70.5 ± 8.6   70.8 ± 9.0        70.5 ± 8.9   71.7 ± 10.4   G: P = 0.917, T: P = 0.079, G × T: P = 0.252
  Fat mass (kg)                   16.8 ± 4.9   16.9 ± 5.4        16.4 ± 5.6   16.3 ± 6.3    G: P = 0.846, T: P = 0.957, G × T: P = 0.773
  BMI (kg/m^2^)                   23.3 ± 2.2   23.4 ± 2.3        24.2 ± 3.6   24.6 ± 4.1    G: P = 0.501, T: P = 0.089, G × T: P = 0.247
  Whole body fat-free mass (kg)   50.9 ± 4.7   51.0 ± 4.6        51.2 ± 5.4   52.5 ± 6.2    G: P = 0.714, T: P = 0.011, G × T: P = 0.037
  Arm and leg lean mass (kg)      23.0 ± 2.3   23.6 ± 2.7        23.4 ± 2.8   24.2 ± 2.9    G: P = 0.695, T: P = 0.001, G × T: P = 0.584

Data are reported as mean ± standard deviation. WP: whey protein; WP + GABA: whey protein + gamma-aminobutyric acid; BMI: body mass index; ANOVA: analysis of variance; G: group effect; T: time effect; G × T: group × time effect.

On the contrary, the WP + GABA group exhibited greater increases in whole body fat-free mass ([Fig. 2a](#F2){ref-type="fig"}) after 12 weeks than the WP group (WP: 146 ± 207 g vs. WP + GABA: 1,340 ± 443 g; P \< 0.05). There was no significant inter-group difference in arm and leg lean mass ([Fig. 2b](#F2){ref-type="fig"}) after 12 weeks (WP: 586 ± 265 g vs. WP + GABA: 765 ± 164 g; P = 0.58).

![Change in body composition after 12 weeks as measured using dual-energy X-ray absorptiometry. (a) Whole body fat-free mass and (b) arm and leg lean mass. Values represent the mean ± standard error for 10 subjects (the whey protein group (WP)) or 11 subjects (the whey protein + gamma-aminobutyric acid group (WP + GABA)). \*P \< 0.05 vs. the WP group.](jocmr-11-428-g002){#F2}

Discussion {#s4}
==========

Our main novel finding was that daily supplementation using GABA and whey protein significantly enhanced whole body fat-free mass after 12 weeks of resistance training among untrained middle-aged men with suboptimal dietary protein intake, which suggests that GABA (in combination with whey protein) may help enhance exercise-induced muscle hypertrophy.

GABA's ability to enhance muscle hypertrophy may be related in part to its ability to increase basal GH concentrations. Concurrently, GH plays an important role in promoting amino acid transport, cellular amino acid uptake, and skeletal muscle growth \[[@R22]-[@R24], [@R33]\]. High amino acid concentrations in muscle cells can promote protein synthesis and muscle hypertrophy \[[@R34]\]. Oral GABA supplementation promotes protein synthesis in various parts (e.g. the brain and gastrocnemius muscle) and higher plasma GH concentrations at rest in rats \[[@R26]\]. Here, resting plasma GH concentrations in the WP + GABA group (10 g whey protein and 100 mg GABA) were significantly higher at weeks 4 and 8 than at baseline. However, in the WP group (10 g whey protein), plasma GH concentrations increased gradually; the only significant difference was at week 8. In addition to GABA, various amino acids (e.g. arginine, lysine, and branched-chain amino acids) can promote GH secretion \[[@R35], [@R36]\]. Therefore, gradually increasing GH concentrations in the WP group may be related to amino acids included in whey powder. Conversely, the earlier increase in GH concentrations in the WP + GABA group may be related to the complementary effects of GABA and whey protein amino acids. The higher plasma GH concentration at rest is thought to promote muscle protein synthesis. Direct intravenous GH administration in young men for increasing basal GH concentration indicated a significant increase in basal muscle protein synthesis \[[@R29]\]. Additionally, GH administration in old women for 4 weeks showed a 50% increase in muscle protein synthesis at rest \[[@R30]\]. Thus, GABA may have partly promoted muscle protein synthesis, leading to increase in whole body fat-free mass by elevating resting plasma GH concentrations. Nevertheless, both groups exhibited attenuations in GH concentrations between weeks 8 and 12. Therefore, any anabolic effect of elevated basal GH concentration may have peaked in weeks 4 - 8. However, more frequent assessment is necessary to detect changes in fat-free mass at an early stage. Hence, future studies are warranted to investigate the relationship between changes in resting GH level and resistance exercise-induced muscle hypertrophy.

GABA has other physiological effects, including sleep quality improvement and fatigue reduction. Sleep deprivation negatively influences exercise performance and post-exercise recovery \[[@R37], [@R38]\]. GABA improves sleep quality by shortening sleep latency and increasing non-rapid eye movement (REM) sleeping time \[[@R18]\]. GABA also reduces acute psychological and physical fatigue by suppressing sympathetic response and increasing parasympathetic response under stressful tasks \[[@R19], [@R39]\]. Although we did not evaluate sleep quality and psychological effects, there is a possibility that these physiological effects of GABA lead to improved motivation during exercise and/or improved post-exercise recovery. Further studies are warranted to investigate these potential benefits of GABA ingestion.

Studies have found that the 6-24-week period of protein supplementation and resistance exercise promoted a 800 - 3,400 g increase in whole body fat-free mass \[[@R03], [@R11]\]. However, we found that the WP group exhibited a relatively small change in fat-free mass, compared to previously reported changes \[[@R03], [@R11]\]. This discrepancy may be related to three factors. The first factor is total protein supplementation amount after resistance exercise that exhibits dose-dependent increase in muscle protein synthesis with plateaus at 20 g and 40 g for young and older individuals, respectively \[[@R40]\]. Therefore, 10-g dosage is considered insufficient for maximal anabolic response \[[@R05], [@R41]\]. Our subjects received a daily 10-g whey protein dose, which may have been insufficient to induce optimal muscle protein synthesis and hypertrophy. The second factor is resistance training intensity and frequency, which can affect muscle mass and strength. A study found that weekly resistance training did not provide significantly greater muscle strength and lean body mass than training three times per week \[[@R42]\]. In this study, untrained subjects performed resistance training twice per week, which may have been insufficient to stimulate maximal muscle hypertrophy. The third factor is low dietary protein intake ([Table 1](#T1){ref-type="table"}). Protein intake was approximately 1 g/kg/day in both groups, which satisfied an Recommended Dietary Allowance of 0.8 g/kg/day but was likely suboptimal to induce maximal hypertrophy. Nevertheless, the WP + GABA group exhibited a 12-week change of \>1 kg in fat-free mass, which was significantly greater than the increase in the WP group (that received the same supplementation and underwent the same training program). Additionally, both groups exhibited similar changes in arm and leg lean masses, suggesting that the enhanced whole body fat-free mass in the WP + GABA group was related to enhanced lean mass in the trunk (rather than in the legs and/or arms). Therefore, these findings may indicate that GABA with whey protein supplementation increases whole body fat-free mass more effectively at low whey protein doses and low-frequency resistance exercise than whey protein supplementation alone.

Conclusions {#s4a}
-----------

To the best of our knowledge, this is the first study to evaluate the effects of GABA in combination with whey protein supplementation on muscular hypertrophy in men during a 12-week program of progressive resistance training. Our results indicate that GABA plus a suboptimal dose of whey protein resulted in significantly enhanced whole body fat-free mass, compared to whey protein alone. Thus, daily supplementation with GABA may be a useful addition to whey protein for enhancing exercise-induced muscle hypertrophy. Nevertheless, further studies are needed to validate our findings, to determine whether GABA directly promotes muscle protein synthesis, and to investigate the mechanism through which GABA enhances lean mass.
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